The FDA approved the first GLP-1 receptor agonist for diabetes management in 2005, and weight-management applications followed years after
Our injections are administered by licensed practitioners in a clean, relaxing setting, and we help you choose the right shot for your goals
not related to contamination or human error)
Early intervention can help prevent the onset of age-related conditions and support the body's natural processes, leading to a longer, healthier life
Despite the side effects, the Phase 2b trial showed that twice-daily danuglipron was effective in reducing body weight and reported mean reductions from -6.9% to -11.7%
While many of the findings cited above were observed in animal studies (and therefore cannot be extrapolated to humans), there is evidence that researchers are actively exploring BCP-157s potential in these areas